ADA 2018: CV Benefits of SGLT-2 Inhibitors

Sanofi is the third key insulin maker to announce reductions in the cost of its products, joining other giants Eli Lilly and Co and Novo Nordisk.

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

Some of the insulin price cuts announced will be effective immediately, others will roll out in April and May; Lilly Chair and CEO calls industry and lawmakers to join the effort.

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Women who gave birth to infants in the highest birthweight category were at a 21% increased risk for prediabetes/diabetes 10 to 14 years later.

The proportion of adults with diabetes and obesity in the US increased from 1999 to 2020, though more adults achieved blood pressure and lipid control during the same period.